LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...
RenovoRx (RNXT) highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference in Las Vegas, Nevada. The abstract published promising pre-clinical data ...
First commercially available cell culture solution for HEK293 cells and perfusion -– optimized for high cell density (HCD), intensified processes and perfusion cultures Additional capabilities for ...
TAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors. “We believe the synergy between RenovoRx’s trans-arterial drug delivery system and ...
Data supports the novel Trans-Arterial Micro-Perfusion (TAMP TM) therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy’s toxicities versus systemic intravenous ...
• Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. • TAMP enables localized, targeted delivery of CF33 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results